IL156618D0 - Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same - Google Patents

Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same

Info

Publication number
IL156618D0
IL156618D0 IL15661801A IL15661801A IL156618D0 IL 156618 D0 IL156618 D0 IL 156618D0 IL 15661801 A IL15661801 A IL 15661801A IL 15661801 A IL15661801 A IL 15661801A IL 156618 D0 IL156618 D0 IL 156618D0
Authority
IL
Israel
Prior art keywords
crystals
fragments
preparation
methods
same
Prior art date
Application number
IL15661801A
Original Assignee
Altus Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US25870400P priority Critical
Application filed by Altus Biologics Inc filed Critical Altus Biologics Inc
Priority to PCT/US2001/049628 priority patent/WO2002072636A2/en
Publication of IL156618D0 publication Critical patent/IL156618D0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host
IL15661801A 2000-12-28 2001-12-26 Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same IL156618D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US25870400P true 2000-12-28 2000-12-28
PCT/US2001/049628 WO2002072636A2 (en) 2000-12-28 2001-12-26 Crystals of whole antibodies and fragments thereof and methods for making and using them

Publications (1)

Publication Number Publication Date
IL156618D0 true IL156618D0 (en) 2004-01-04

Family

ID=22981767

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15661801A IL156618D0 (en) 2000-12-28 2001-12-26 Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same

Country Status (10)

Country Link
US (2) US7833525B2 (en)
EP (2) EP2325205A3 (en)
JP (1) JP4731793B2 (en)
KR (3) KR20030074693A (en)
AU (1) AU2002256971B2 (en)
CA (1) CA2433353C (en)
IL (1) IL156618D0 (en)
NZ (1) NZ526720A (en)
WO (1) WO2002072636A2 (en)
ZA (1) ZA200305035B (en)

Families Citing this family (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
MXPA02007756A (en) 2000-02-10 2004-09-10 Abbott Lab Antibodies that bind human interleukin 18 and methods of making and using.
AT511857T (en) * 2000-02-16 2011-06-15 Genentech Inc Anti-april monoclonal antibody and its use for the treatment of immune diseases or cancer
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2003000014A2 (en) * 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
BR0211614A (en) * 2001-08-03 2006-10-31 Genentech Inc tacis and br3 polypeptide and their uses
WO2003041637A2 (en) * 2001-11-09 2003-05-22 Centocor, Inc. Lyophilized monoclonal antibody compositions
CN102764436A (en) 2002-07-19 2012-11-07 艾博特生物技术有限公司 Treatment of TNF alpha related disorders
NZ537781A (en) * 2002-07-25 2008-04-30 Genentech Inc Taci antibodies and uses thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
WO2004022096A1 (en) * 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
ES2633311T3 (en) * 2002-12-16 2017-09-20 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2003300126B2 (en) * 2002-12-31 2010-04-01 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
EP2460530A3 (en) 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
US20050053666A1 (en) * 2002-12-31 2005-03-10 Stelios Tzannis Antibody-containing particles and compositions
CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
CN1750844B (en) 2003-02-21 2010-09-08 Tanox Inc Use of lectin path specific CIq inhibitor for preparing pharmaceutical for preventing and treating tissue damage
US20070065433A1 (en) * 2003-02-21 2007-03-22 Mollnes Tom E Methods and compositions for the treatment of meconium aspiration syndrome
LT2335725T (en) 2003-04-04 2017-01-25 Genentech, Inc. High concentration antibody and protein formulations
US8329169B2 (en) 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
AU2004256042A1 (en) * 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
CA2566075A1 (en) * 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
AU2004262014B2 (en) * 2003-08-01 2010-06-17 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
DE10355251A1 (en) 2003-11-26 2005-06-23 Merck Patent Gmbh Water-based pharmaceutical preparation for treatment of tumors has active ingredient effective against receptor of endothelial growth factor receptor
DE10355904A1 (en) 2003-11-29 2005-06-30 Merck Patent Gmbh Solid forms of anti-EGFR antibodies
JP2008519757A (en) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトングMerck Patent Gesellschaft mit beschraenkter Haftung Anti-EGFR antibody solid
US20050186175A1 (en) * 2004-02-20 2005-08-25 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on benzilic acid esters and soluble TNF receptor fusion proteins
TWI556829B (en) 2004-04-09 2016-11-11 Abbvie Biotechnology Ltd Multiple variable dose therapy for the treatment of TNFα-related disorders
ZA200608982B (en) * 2004-05-05 2008-06-25 Genentech Inc Preventing autoimmune disease by using an anti-CD20 antibody
DK1758558T3 (en) * 2004-05-12 2014-01-20 Baxter Int Oligonucleotide-containing microspheres and their use in the manufacture of a drug for the treatment of type 1 diabetes
ES2422757T3 (en) 2004-05-12 2013-09-13 Baxter Int therapeutic use of nucleic acid microspheres
ZA200610158B (en) * 2004-06-04 2008-07-30 Genentech Inc Method for treating multiple sclerosis
SV2006002131A (en) * 2004-06-04 2006-01-26 Genentech Inc Using an antibody to treat lupus
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp Antibodies against human interleukin-13 and uses thereof
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
NZ552713A (en) * 2004-07-23 2010-06-25 Genentech Inc Crystallization of anti-VEGF antibodies or fragments thereof using divalent cations
EP1812060A2 (en) * 2004-10-05 2007-08-01 Genentech, Inc. Method for treating vasculitis
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
CA2590163A1 (en) * 2005-01-13 2006-07-20 Genentech, Inc. Treatment method
DOP2006000029A (en) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and use thereof. (Variants of an antibody and uses thereof)
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
PT1850874E (en) 2005-02-23 2013-12-02 Genentech Inc Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (en) * 2005-04-15 2007-05-09 Genentech Inc Treatment of inflammatory bowel disease (IBD)
MX2007014440A (en) 2005-05-16 2008-02-11 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis.
CN101223448B (en) * 2005-05-20 2012-01-18 健泰科生物技术公司 Pretreatment of a biological sample from an autoimmune disease subject
CN103145839A (en) 2005-06-30 2013-06-12 Abbvie 公司 IL-12/P40 binding proteins
CA2612937C (en) * 2005-07-22 2014-05-06 Amgen Inc. Concentrated protein lyophilates, methods, and uses
JP2012228248A (en) * 2005-08-19 2012-11-22 Abbott Lab Dual variable domain immunoglobulin and use thereof
EP2495257A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500354A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
CA2862540C (en) * 2005-09-21 2018-07-31 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
WO2007039256A2 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
BRPI0618085A2 (en) 2005-11-01 2011-08-16 Abbott Biotech Ltd Processes and kits for diagnosis of ankylosing spondylitis using biomarkers
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (en) * 2005-11-23 2016-12-14 Genentech, Inc. Methods and compositions related to b cell assays
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
CA2647029A1 (en) 2006-04-05 2007-10-18 Abbott Biotechnology Ltd. Antibody purification
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2708242A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of ankylosing spondylitis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CN103316402A (en) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 Automatic injection device
AU2007275654A1 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania WSX-1/p28 as a target for anti-inflammatory responses
AU2007281737B2 (en) 2006-08-04 2013-09-19 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CN104774266A (en) 2006-09-08 2015-07-15 艾伯维巴哈马有限公司 Interleukin-13 binding proteins
PE09802008A1 (en) * 2006-10-12 2008-09-02 Genentech Inc Anti-lymphotoxin alpha
NZ576133A (en) * 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
US9675696B2 (en) * 2006-11-14 2017-06-13 Warsaw Orthopedic, Inc. Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
BRPI0809209A2 (en) 2007-03-29 2014-09-02 Abbott Lab Crystaline il-12 anti-human antibodies
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
AU2008242842B2 (en) * 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
EP2137215A2 (en) * 2007-04-23 2009-12-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
US20100310548A1 (en) * 2007-10-15 2010-12-09 Biogen Idec Ma Inc. Methods of Manufacturing a Biologic Using a Stable Storage Intermediate
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2010130467A (en) * 2007-12-21 2012-01-27 Дженентек, Инк. (Us) Crystallization anti-cd20-antibodies
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2247310A4 (en) * 2008-01-30 2012-06-27 Abbott Lab Compositions and methods for crystallizing antibody fragments
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2717569A1 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3059248A1 (en) 2008-05-09 2016-08-24 Abbvie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (rage) and uses thereof
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Immunoglobulins with two variable domains and their application
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
EP2810654A1 (en) 2008-07-08 2014-12-10 AbbVie Inc. Prostaglandin E2 binding proteins and uses thereof
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
TW201016233A (en) * 2008-07-15 2010-05-01 Genentech Inc Methods of treating autoimmune diseases using CD4 antibodies
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2742802A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CN102300879A (en) * 2008-12-04 2011-12-28 雅培制药有限公司 Dual variable domain immunoglobulins and their use
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
EP2810652A3 (en) 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
KR20110128333A (en) 2009-03-06 2011-11-29 제넨테크, 인크. Antibody formulation
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
KR101721906B1 (en) 2009-04-29 2017-03-31 애브비 바이오테크놀로지 리미티드 Automatic injection device
WO2010138809A1 (en) * 2009-05-28 2010-12-02 University Of Virginia Patent Foundation Compositions and methods for a membrane protein crystallization screening kit
US20120104413A1 (en) 2009-06-29 2012-05-03 Bougrov Vladislav E Light emitting semiconductor device and method for manufacturing
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
JP5800809B2 (en) 2009-07-10 2015-10-28 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. TLR3 binding agent
CN102770151B (en) 2009-08-03 2018-07-31 因卡伯实验室有限责任公司 For stimulating what incretin in enteron aisle generated to swallow formula capsule and method
KR20120059553A (en) 2009-08-14 2012-06-08 제넨테크, 인크. Biological markers for monitoring patient response to vegf antagonists
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013504595A (en) 2009-09-11 2013-02-07 ジェネンテック, インコーポレイテッド Methods for identifying patients with increased likelihood of response to anticancer drugs
JP5491119B2 (en) 2009-10-02 2014-05-14 日東電工株式会社 Pharmaceutical composition containing drug-containing microparticles and method for producing the same
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
CN102656190A (en) 2009-12-08 2012-09-05 雅培股份有限两合公司 Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
CA2781725A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of treating interstitial cystitis
US8764733B2 (en) 2010-12-23 2014-07-01 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) * 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en) 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MX2012008985A (en) 2010-02-02 2012-09-07 Abbott Biotech Ltd Methods and compositions for predicting responsiveness to treatment with tnf-î± inhibitor.
RU2573994C2 (en) 2010-02-10 2016-01-27 Иммьюноджен, Инк Anti-cd20 antibodies and thereof application
KR101853278B1 (en) 2010-03-02 2018-05-02 애브비 인코포레이티드 Therapeutic dll4 binding proteins
EP2555797A4 (en) * 2010-04-07 2014-02-12 Abbvie Inc Tnf- binding proteins
CN102933601B (en) 2010-04-15 2016-06-08 Abbvie 公司 β-amyloid binding protein
US9180244B2 (en) 2010-04-21 2015-11-10 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2575884B1 (en) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
CA2805708A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
MX2013000667A (en) 2010-07-19 2013-02-27 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy.
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
KR20130100118A (en) 2010-08-03 2013-09-09 아비에 인코포레이티드 Dual variable domain immunoglobulins and uses therof
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
CA2808577C (en) 2010-08-19 2018-09-25 Abbott Laboratories Anti-ngf antibodies and their use
JP5952816B2 (en) * 2010-08-19 2016-07-13 プロビオドルグ エージー Crystal structure of glutaminyl cyclase
PE02292014A1 (en) 2010-08-26 2014-03-27 Abbvie Inc Immunoglobulins Dual variable domain and uses thereof
CA2821976A1 (en) 2010-12-21 2012-09-13 Abbvie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
WO2012095432A2 (en) 2011-01-12 2012-07-19 Innate Pharma Tlr3 binding agents
MY166835A (en) 2011-01-24 2018-07-23 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
AU2015230852B2 (en) * 2011-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. High concentration antibody formulations
MX338078B (en) * 2011-03-25 2016-04-01 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof.
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
BR112014003110A2 (en) * 2011-08-10 2018-10-09 Lab Francais Du Fractionnement composition, method for producing a highly galactosylated population of antibodies, mammary gland epithelial cells and tramsgenic non-human mammal
HUE044352T2 (en) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
TW201326207A (en) 2011-10-24 2013-07-01 Abbvie Inc Immunobinders directed against TNF
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
UY34558A (en) 2011-12-30 2013-07-31 Abbvie Inc Dual specific binding proteins directed against IL-13 and / or IL-17
CN104203268A (en) 2012-01-13 2014-12-10 霍夫曼-拉罗奇有限公司 Biological markers for identifying patients for treatment with vegf antagonists
DK2807192T3 (en) 2012-01-27 2018-07-23 Abbvie Deutschland Composition and procedure for diagnostication and treatment of diseases related to neurite degeneration
CA2865082A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
CN104271157A (en) 2012-03-30 2015-01-07 霍夫曼-拉罗奇有限公司 Diagnostic methods and compositions for treatment of cancer
AU2013258006B2 (en) * 2012-05-11 2016-04-28 Novartis Ag Crystallization methods for purification of monoclonal antibodies
CN104379603B (en) 2012-05-31 2017-11-07 先天制药公司 TLR3 bonding agents
JP2015521461A (en) 2012-06-06 2015-07-30 ゾエティス・エルエルシー Caninized anti-NGF antibody and method thereof
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
WO2013189516A1 (en) * 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
EP2861251A1 (en) 2012-06-18 2015-04-22 Apeiron Biologics AG Method for treating a gd2 positive cancer
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
TW201402608A (en) 2012-07-12 2014-01-16 Abbvie Inc IL-1 binding proteins
JP6348115B2 (en) 2012-10-26 2018-06-27 ザ ユニバーシティー オブ クイーンズランド Use of endocytosis inhibitors and antibodies for cancer therapy
WO2014071074A2 (en) 2012-11-01 2014-05-08 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
CN105308068A (en) 2013-02-13 2016-02-03 法国化学与生物科技实验室 Highly galactosylated anti-tnf-alpha antibodies and uses thereof
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US9790478B2 (en) 2013-03-14 2017-10-17 Abbott Laboratories HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
JP2016512242A (en) 2013-03-14 2016-04-25 アボット・ラボラトリーズAbbott Laboratories HCV core lipid binding domain monoclonal antibody
WO2014158272A1 (en) 2013-03-14 2014-10-02 Abbott Laboratories Hcv antigen-antibody combination assay and methods and compositions for use therein
BR112015023797A2 (en) 2013-03-15 2017-10-24 Abbvie Inc dual specificity binding proteins directed against il-1b and / or il-17
RU2015141520A (en) 2013-04-16 2017-05-22 Дженентек, Инк. Pertuzumab options and their analytical characteristics
EP2805730A1 (en) 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
EA201690346A1 (en) 2013-08-07 2016-08-31 Алексион Фармасьютикалз, Инк. Protein biomarkers of atypical hemolytic uremic syndrome
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US20150065781A1 (en) 2013-08-30 2015-03-05 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US20160256460A1 (en) 2013-11-01 2016-09-08 Bergen Teknologioverføring As Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
CN105722523A (en) * 2013-11-15 2016-06-29 豪夫迈·罗氏有限公司 Methods for viral inactivation using eco-friendly detergents
EA201692109A1 (en) 2014-05-01 2017-03-31 Дженентек, Инк. Options of antibodies to factor d and their application
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
AU2015289967A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
CN106460067A (en) 2014-07-14 2017-02-22 豪夫迈·罗氏有限公司 Diagnostic methods and compositions for treatment of glioblastoma
JP2017537891A (en) 2014-10-31 2017-12-21 ジェネンテック, インコーポレイテッド Anti-IL-17A and IL-17F cross-reactive antibody variants, and compositions containing them, methods of making them, and methods of using
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
CN108064170A (en) 2015-05-29 2018-05-22 豪夫迈·罗氏有限公司 PD-L1 promoter methylations in cancer
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
KR20180075537A (en) 2015-10-06 2018-07-04 제넨테크, 인크. Methods for treating multiple sclerosis
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2018125589A1 (en) 2016-12-28 2018-07-05 Genentech, Inc. Treatment of advanced her2 expressing cancer
KR20190104554A (en) 2017-01-17 2019-09-10 제넨테크, 인크. Subcutaneous HER 2 Antibody Formulations
CN110337450A (en) 2017-03-02 2019-10-15 基因泰克公司 The adjuvant treatment of HER2 positive breast cancer
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US4334024A (en) 1980-11-03 1982-06-08 Sarjit Johal Preparation and crystallization of fraction I protein from plant sources
DE3327709A1 (en) * 1983-07-29 1985-02-07 Hoechst Ag Insulin derivative-crystal suspensions, process for their preparation and their use
DE3419782C1 (en) 1984-05-26 1985-11-14 Goedecke Ag Spherical particles with protein immunoadsorbent properties and processes for their preparation
US6727278B1 (en) * 1986-08-27 2004-04-27 Dms Pharmaceutical Inc. Pharmaceutically active agents that impede amyloid formation in vivo
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JP2975109B2 (en) * 1989-12-21 1999-11-10 ノボ ノルディスク アクティーゼルスカブ Crystallization method of enzyme
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5751453A (en) * 1991-12-06 1998-05-12 Ncr Corporation Liquid crystal display with pen-input capability
WO1994010980A1 (en) * 1992-11-16 1994-05-26 Corporation Of Mercer University Compositions using microencapsulated neutralizing antibodies
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
AU6960696A (en) 1995-08-30 1997-03-19 Ariad Pharmaceuticals, Inc. Crystalline zap family proteins
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
DE60027877T2 (en) 1999-03-05 2006-12-28 Genencor International, Inc., Palo Alto Process for the fast manufacture of crystalles with desirable morphology
AU782916B2 (en) * 1999-06-09 2005-09-08 Robert E. Sievers Supercritical fluid-assisted nebulization and bubble drying
EP1190123B1 (en) * 1999-06-10 2002-10-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Encapsulation of crystals via multilayer coatings
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
FR2802445B1 (en) * 1999-12-15 2002-02-15 Separex Sa Method and fine particles by trapping capture device within a solid blend type of dry ice
US20020067800A1 (en) * 2000-10-19 2002-06-06 Janet Newman Apparatus and method for identification of crystals by in-situ X-ray diffraction
US6562952B1 (en) * 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US6955717B2 (en) * 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
US7144903B2 (en) * 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
WO2003000014A2 (en) * 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BRPI0809209A2 (en) * 2007-03-29 2014-09-02 Abbott Lab Crystaline il-12 anti-human antibodies

Also Published As

Publication number Publication date
NZ526720A (en) 2007-11-30
ZA200305035B (en) 2005-11-30
US20020136719A1 (en) 2002-09-26
WO2002072636A8 (en) 2004-02-26
US20090093617A1 (en) 2009-04-09
JP2005502589A (en) 2005-01-27
EP2325205A2 (en) 2011-05-25
US9310379B2 (en) 2016-04-12
CA2433353A1 (en) 2002-09-19
KR20030074693A (en) 2003-09-19
WO2002072636A3 (en) 2003-04-17
US7833525B2 (en) 2010-11-16
EP1345968A2 (en) 2003-09-24
KR20080043858A (en) 2008-05-19
EP2325205A3 (en) 2011-10-12
CA2433353C (en) 2017-03-21
JP4731793B2 (en) 2011-07-27
KR20100031769A (en) 2010-03-24
WO2002072636A2 (en) 2002-09-19
KR100923514B1 (en) 2009-10-27
AU2002256971B2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
DE69940153D1 (en) Method and device for the early diagnosis of sub-acids, potentially catastrophal diseases
DE60238143D1 (en) Compositions and methods for the diagnosis of tumors
TWI316088B (en) Anti-tnf alpha antibodies and their uses
GB2374415B (en) Human antibodies as detection reagents
EP1470146B8 (en) Antibodies against the muc18 antigen
DE60142500D1 (en) Human monoclonal antibodies against the costimulatory signal transduction molecule AILIM and pharmaceutical uses thereof
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
SI2940044T1 (en) Anti-tnf alpha antibodies for use in therapy
IL150908D0 (en) Single phase gels and methods for the preparation thereof
AU2002258808A1 (en) Humanized antibodies
SI1362105T1 (en) Anti-interferon-alpha antibodies
IL170685A (en) Protein conjugate, compositions comprising the same and methods for producing the same
PL357939A1 (en) Multivalent antibodies and uses therefor
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
AU3659701A (en) System and method for the analysis of bodily fluids
IL161968D0 (en) Anti-il-6 antibodies, compositions, methods and uses
MXPA03007440A (en) Cubic liquid crystalline compositions and methods for their preparation.
BR9912227B1 (en) method for early in vitro diagnosis of carcinomas and their early stages; and kit for performing the method.
ZA200006312B (en) Antibodies to CD23, derivatives thereof, and their therapeutic uses.
ZA9807540B (en) Process for the preparation of stanol esters, and use thereof.
PT1372503E (en) Osteosynthetic device for the spinal-medula and their preparation method
NL300390I2 (en) Anti-IL-12 antibodies, compositions, methods and uses
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
LTPA2017008I1 (en) Anti-TNF antibodies, compositions, methods, and uses
AU2003302031A1 (en) Modified biological substance, process for producing the same, and intermediate